Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acarbose and lymphocytic colitis.

T Piche, V Raimondi, S Schneider

    Lancet (London, England)
    |November 10, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Acarbose, a medication for type 2 diabetes, can cause lymphocytic colitis. Immunopathological analysis confirmed drug-induced immune-cell activation in the colon.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Large iatrogenic colonic perforation treated by endoscopic suturing].

    Gastroenterologie clinique et biologique·2010
    Same author

    Low risk of irritable bowel syndrome after Clostridium difficile infection.

    Canadian journal of gastroenterology = Journal canadien de gastroenterologie·2007
    Same author

    Review article: yeast as probiotics -- Saccharomyces boulardii.

    Alimentary pharmacology & therapeutics·2007
    Same author

    [Cholangiography by magnetic resonance for detection of cholelithiasis: comparison with endoscopic retrograde cholangiography, operative cholangiography and percutaneous cholangiography].

    Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru·2006
    Same author

    Effects of refeeding by cyclic enteral nutrition on body composition: comparative study of elderly and younger patients.

    Clinical nutrition (Edinburgh, Scotland)·2006
    Same author

    Correction of protein-energy malnutrition in older adults: effects of a short-term aerobic training program.

    Clinical nutrition (Edinburgh, Scotland)·2006
    Same journal

    Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

    Lancet (London, England)·2026
    Same journal

    Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

    Lancet (London, England)·2026
    Same journal

    Inherited retinal degenerations: clinical phenotypes and emerging therapies.

    Lancet (London, England)·2026
    Same journal

    Documenting hospice care.

    Lancet (London, England)·2026
    Same journal

    After the wood chipper.

    Lancet (London, England)·2026
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    See all related articles

    Area of Science:

    • Gastroenterology
    • Immunology
    • Pharmacology

    Background:

    • Lymphocytic colitis is an inflammatory condition of the colon.
    • Acarbose is an alpha-glucosidase inhibitor used to manage type 2 diabetes mellitus.

    Observation:

    • A patient developed symptoms suggestive of colitis.
    • The patient was concurrently taking acarbose for diabetes management.

    Findings:

    • Immunopathological examination revealed evidence of lymphocytic colitis.
    • Rechallenge with acarbose exacerbated the colonic immune-cell activation, confirming the drug as the causative agent.

    Implications:

    • This case highlights a potential adverse drug reaction of acarbose.
    • Clinicians should consider acarbose-induced lymphocytic colitis in patients presenting with relevant symptoms.
  • Further research into the immunopathogenesis of drug-induced colitis is warranted.